Clinical Trials Logo
  1. Home
  2. Lung Transplant Infection
  3. NCT02351180

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

Lung Transplant Infection Clinical Trial

Official title:
A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients

Clinical Trial Summary

The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.

Clinical Trial Description

Community-acquired respiratory viral (CARV) infections after lung transplantation are associated with an increased risk for the development of chronic lung allograft dysfunction (CLAD) after lung transplantation. The exact mechanisms whereby CARV infections increase this risk are unknown. We propose that viral infection results in airway epithelial cell injury and the expression of injury-response genes that provide signals that initiate immunologic and non-immunologic pathways that result in the airway remodeling characteristic of obliterative bronchiolitis, the predominant pathology of CLAD. Systemic and inhaled corticosteroids are frequently used as anti-inflammatory agents to treat the peribronchiolar inflammation seen in viral bronchiolitis. Beneficial effects from corticosteroids have been reported, but this has not been demonstrated in lung transplant recipients. The aim of this single center, randomized, double blind, placebo controlled study is to evaluate the short and long term effects of a 6 month course of inhaled beclomethasone on adult lung transplant recipients with CARV infection. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02351180
Study type Interventional
Source Washington University School of Medicine
Contact
Status Completed
Phase Phase 1/Phase 2
Start date February 1, 2017
Completion date January 31, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03112044 - Lung Transplant HCV, Pilot Study Early Phase 1
Terminated NCT03905447 - The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. Phase 2
Completed NCT01952470 - Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant. Phase 2
Recruiting NCT05050955 - AlloSure Lung Assessment and Metagenomics Outcomes Study
Completed NCT01419678 - Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients N/A
Completed NCT05721079 - Extracorporeal Photopheresis (ECP) After Lung Transplantation N/A
Recruiting NCT05960383 - Molecular vs Conventional Microbiologic Diagnosis for Infections in Lung Transplantation
Withdrawn NCT04652050 - Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation
Recruiting NCT04017338 - Transplantation Using Hepatitis C Positive Donors, A Safety Trial Phase 3
Recruiting NCT03545919 - Clinical Significance of Community-acquired Respiratory Virus Infection and Longitudinal Analysis of the Lung Microbiome in Lung Transplantation